Continued Access to the Endogenex System for Participants in the ReCET Pivotal Study

Inclusion Criteria: * Randomized to the sham control arm in the ReCET Study and completed their 12-month study visit. * HbA1c of 7.0-10.5%, inclusive * BMI \<40 kg/m2, inclusive. * Agree not to donate blood during participation in the study. * Able to comply with study requirements and understand and sign the Informed Consent Form. * Women of childbearing potential must be not pregnant and using an acceptable method of contraception throughout the study. * Willing and able to comply with study visits and study tasks as required per protocol. Exclusion Criteria: * Diagnosed with type 1 diabetes. * History of diabetic ketoacidosis or hyperosmolar nonketotic coma. * Current use of insulin, or previous use of any types of insulin for \>1 month at any time (except for treatment of gestational diabetes) in last 2 years. * Hypoglycemic unawareness. * History of ≥1 severe hypoglycemia episode in past 6 months * Discontinuation of a GLP-1RA or a GLP-1/GIP dual-agonist within 6 months of the screening visit following at least one month of treatment. * Known autoimmune disease, including but not limited to, celiac disease, or pre-existing symptoms of systemic lupus erythematosus, scleroderma or other autoimmune connective tissue disorder, or as evidenced by a positive anti-glutamic acid decarboxylase (GAD) test. * Previous GI surgery that has changed GI anatomy or could limit treatment of the duodenum, such as Billroth 2, Roux-en-Y gastric bypass, gastric band or other similar proced…